BLAB — Britannia Life Sciences Income Statement
0.000.00%
Last trade - 00:00- CA$9.74m
- CA$20.51m
- CA$7.57m
- 29
- 34
- 35
- 23
Annual income statement for Britannia Life Sciences, fiscal year end - March 31st, CAD millions except per share, conversion factor applied.
2019 November 30th | 2020 November 30th | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.974 | 0.032 | 7.3 | 6.4 | 7.57 |
| Cost of Revenue | |||||
| Gross Profit | 0.338 | 0.02 | 5.26 | 4.64 | 4.85 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 6.39 | 1.66 | 16.9 | 4.84 | 12.2 |
| Operating Profit | -5.41 | -1.62 | -9.59 | 1.56 | -4.64 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -7.13 | -3.2 | -13.3 | 5.86 | -4.47 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -7.13 | -3.2 | -14 | 5.84 | -4.4 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -7.13 | -3.2 | -15.5 | 5.08 | -4.77 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -7.13 | -3.2 | -15.5 | 5.08 | -4.77 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.19 | -0.439 | -0.082 | 0.023 | -0.01 |